Windlas Biotech (543329) 주식 개요계약 개발 및 제조 조직(CDMO)인 윈들라스 바이오테크는 인도 및 국제적으로 의약품을 제조 및 거래하는 기업입니다. 자세히 보기543329 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적1/6재무 건전성6/6배당3/6강점가격 대비 수익 비율(26.1x)은 Life Sciences 업계 평균(41.5x)보다 낮습니다.지난 5년 동안 수입이 매년 18% 증가했습니다.위험 분석재무 결과에 영향을 미치는 대규모 일회성 항목모든 위험 점검 보기543329 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,905 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,905 investors already sharing narrativesYour Fair Value₹Current Price₹839.8516.0% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture019b2016201920222025202620282031Revenue ₹19.0bEarnings ₹1.4bAdvancedSet Fair ValueView all narrativesWindlas Biotech Limited 경쟁사Tarsons ProductsSymbol: NSEI:TARSONSMarket cap: ₹16.4bBorosil ScientificSymbol: BSE:544184Market cap: ₹14.5bVimta LabsSymbol: BSE:524394Market cap: ₹24.7bDishman Carbogen AmcisSymbol: NSEI:DCALMarket cap: ₹30.6b가격 이력 및 성과Windlas Biotech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹839.8552주 최고가₹1,095.0052주 최저가₹699.35베타0.271개월 변동2.56%3개월 변동-3.66%1년 변동-10.21%3년 변동154.23%5년 변동n/aIPO 이후 변동106.50%최근 뉴스 및 업데이트New Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Jul 04Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.04b (up 19% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.4% (down from 8.0% in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • Jul 02Dividend increased to ₹6.30Dividend of ₹6.30 is 8.6% higher than last year. Ex-date: 16th July 2026 Payment date: 22nd August 2026 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 16% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 30% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공고 • Jun 30Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026, at 13:00 Indian Standard Time.Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026더 많은 업데이트 보기Recent updatesNew Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Jul 04Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.04b (up 19% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.4% (down from 8.0% in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • Jul 02Dividend increased to ₹6.30Dividend of ₹6.30 is 8.6% higher than last year. Ex-date: 16th July 2026 Payment date: 22nd August 2026 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 16% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 30% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공고 • Jun 30Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026, at 13:00 Indian Standard Time.Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026공고 • Apr 17Windlas Biotech Limited (NSEI:WINDLAS) announces an Equity Buyback for 470,000 shares, representing 2.23% for INR 470 million.Windlas Biotech Limited (NSEI:WINDLAS) announces a share repurchase program. Under the program, the company will repurchase up to 470,000 shares, representing 2.23% of its issued share capital, for INR 470 million. The company will repurchase the shares at a price of INR 1,000 per equity share, payable in cash. The buyback is proposed to be made on a proportionate basis. The 15% of the number of equity shares which the company proposes to repurchase or number of equity shares entitled as per the shareholding of small shareholders as on the record date, whichever is higher, shall be reserved for the small shareholders. The record date for the purpose of ascertaining the eligibility of shareholders for the repurchase of shares is April 24, 2026. As of March 31, 2026, the company had 21,106,229 shares outstanding.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹7.12 (vs ₹7.45 in 3Q 2025)Third quarter 2026 results: EPS: ₹7.12 (down from ₹7.45 in 3Q 2025). Revenue: ₹2.38b (up 22% from 3Q 2025). Net income: ₹150.0m (down 3.7% from 3Q 2025). Profit margin: 6.3% (down from 8.0% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jan 28Windlas Biotech Limited to Report Q3, 2026 Results on Feb 05, 2026Windlas Biotech Limited announced that they will report Q3, 2026 results on Feb 05, 2026Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹8.48 (vs ₹7.49 in 2Q 2025)Second quarter 2026 results: EPS: ₹8.48 (up from ₹7.49 in 2Q 2025). Revenue: ₹2.26b (up 21% from 2Q 2025). Net income: ₹178.0m (up 14% from 2Q 2025). Profit margin: 7.9% (down from 8.4% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.공고 • Oct 29Windlas Biotech Limited to Report Q2, 2026 Results on Nov 06, 2025Windlas Biotech Limited announced that they will report Q2, 2026 results on Nov 06, 2025Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹8.43 (vs ₹6.47 in 1Q 2025)First quarter 2026 results: EPS: ₹8.43 (up from ₹6.47 in 1Q 2025). Revenue: ₹2.15b (up 23% from 1Q 2025). Net income: ₹176.6m (up 31% from 1Q 2025). Profit margin: 8.2% (up from 7.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.공고 • Aug 09Windlas Biotech Limited to Report Q1, 2026 Results on Aug 12, 2025Windlas Biotech Limited announced that they will report Q1, 2026 results on Aug 12, 2025공고 • Jul 29Windlas Biotech Limited Approves Final Dividend for the Financial Year 2024-25Windlas Biotech Limited announced that at the AGM held on July 28, 2025 approved Final Dividend of INR 5.80/- per Equity Share for the financial year 2024-25.Upcoming Dividend • Jul 14Upcoming dividend of ₹5.80 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 27 August 2025. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.4%).공고 • Jul 06Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025, at 13:00 Indian Standard Time.Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹29.19 (vs ₹27.97 in FY 2024)Full year 2025 results: EPS: ₹29.19 (up from ₹27.97 in FY 2024). Revenue: ₹7.78b (up 23% from FY 2024). Net income: ₹609.9m (up 4.8% from FY 2024). Profit margin: 7.8% (down from 9.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 14Windlas Biotech Limited to Report Q4, 2025 Results on May 22, 2025Windlas Biotech Limited announced that they will report Q4, 2025 results on May 22, 2025Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,071, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 320% over the past three years.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹821, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 249% over the past three years.Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹7.45 (vs ₹7.26 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.45 (up from ₹7.26 in 3Q 2024). Revenue: ₹1.95b (up 20% from 3Q 2024). Net income: ₹155.8m (up 3.2% from 3Q 2024). Profit margin: 8.0% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹844, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 227% over the past three years.공고 • Feb 03Windlas Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025Windlas Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025공고 • Jan 10Windlas Biotech Limited Receives Good Manufacturing Practices Certification for New Injectable Facility from the Food Safety & Drugs Administration Authority of UttarakhandWindlas Biotech Limited announced that it has received Good Manufacturing Practices (GMP) certification for its new Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.49 (up from ₹6.75 in 2Q 2024). Revenue: ₹1.92b (up 26% from 2Q 2024). Net income: ₹156.6m (up 12% from 2Q 2024). Profit margin: 8.2% (down from 9.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).공고 • Nov 05Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Windlas Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,119, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 271% over the past three years.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹997, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 203% over the past three years.공고 • Sep 26Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at its AGM held on September 24, 2024, approved final dividend of INR 5.50 per equity share for the financial year 2023-24.Declared Dividend • Aug 31Dividend increased to ₹5.50Dividend of ₹5.50 is 38% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 25% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 79% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.공고 • Aug 30Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.공고 • Aug 29Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at the AGM to be held on September 24, 2024, the shareholders proposed a final dividend of INR 5.50 per equity share for the financial year 2023-24.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024)First quarter 2025 results: EPS: ₹6.47 (up from ₹5.79 in 1Q 2024). Revenue: ₹1.79b (up 24% from 1Q 2024). Net income: ₹134.8m (up 12% from 1Q 2024). Profit margin: 7.5% (down from 8.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.공고 • Aug 02Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Windlas Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹800, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 143% over the past year.Reported Earnings • May 21Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023)Full year 2024 results: EPS: ₹27.97 (up from ₹19.70 in FY 2023). Revenue: ₹6.44b (up 26% from FY 2023). Net income: ₹581.9m (up 37% from FY 2023). Profit margin: 9.0% (up from 8.3% in FY 2023). The increase in margin was driven by higher revenue.Buy Or Sell Opportunity • May 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.7% to ₹550. The fair value is estimated to be ₹454, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.공고 • May 12Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024Windlas Biotech Limited announced that they will report Q4, 2024 results on May 20, 2024Buy Or Sell Opportunity • Apr 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₹558. The fair value is estimated to be ₹459, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.Buy Or Sell Opportunity • Feb 23Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₹547. The fair value is estimated to be ₹456, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023)Third quarter 2024 results: EPS: ₹7.26 (up from ₹4.23 in 3Q 2023). Revenue: ₹1.65b (up 38% from 3Q 2023). Net income: ₹151.0m (up 64% from 3Q 2023). Profit margin: 9.1% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue.공고 • Jan 31Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024Windlas Biotech Limited announced that they will report Q3, 2024 results on Feb 08, 2024Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹528, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 22x in the Life Sciences industry in India. Total returns to shareholders of 118% over the past year.Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023)Second quarter 2024 results: EPS: ₹6.75 (up from ₹5.59 in 2Q 2023). Revenue: ₹1.56b (up 18% from 2Q 2023). Net income: ₹140.3m (up 15% from 2Q 2023). Profit margin: 9.0% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses.공고 • Oct 31Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023Windlas Biotech Limited announced that they will report first half, 2024 results on Nov 08, 2023공고 • Sep 13Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23Windlas Biotech Limited at the AGM held on September 12, 2023, the shareholders approved a final dividend of INR 4 per equity share for the financial year 2022-23.Upcoming Dividend • Aug 29Upcoming dividend of ₹4.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 September 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.6%).공고 • Aug 19+ 1 more updateWindlas Biotech Limited, Annual General Meeting, Sep 12, 2023Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023, at 12:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2023, together with the Reports of the Auditors and the Board of Directors thereon; to consider declare a Final Dividend; to consider and appoint a Director in place of Mr. Hitesh Windlass, Managing Director who is liable to retire by rotation and being eligible, offers himself for re-appointment; and to transact such other business matters.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹384, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past year.Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023)First quarter 2024 results: EPS: ₹5.79 (up from ₹4.50 in 1Q 2023). Revenue: ₹1.47b (up 23% from 1Q 2023). Net income: ₹120.7m (up 23% from 1Q 2023). Profit margin: 8.2% (in line with 1Q 2023).공고 • Aug 01Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023Windlas Biotech Limited announced that they will report Q1, 2024 results on Aug 08, 2023Reported Earnings • May 06Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022)Full year 2023 results: EPS: ₹19.70 (up from ₹18.58 in FY 2022). Revenue: ₹5.23b (up 12% from FY 2022). Net income: ₹426.3m (up 12% from FY 2022). Profit margin: 8.1% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses.공고 • May 06Windlas Biotech Limited Recommends DividendWindlas Biotech Limited at its board meeting held on May 5, 2023 Recommended a Dividend of INR 4.00/- per Equity Share of face value of INR 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM.공고 • Feb 10Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive OfficerWindlas Biotech Limited announced that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Ms. Komal Gupta as the Chief Executive Officer and Key Managerial Personnel of the Company with effect from February 08, 2023. Ms. Komal Gupta holds a bachelor's degree in commerce from Dr. Babasaheb Ambedkar Marathwada University. She is a fellow member of the Institute of Chartered Accountants of India, an associate member of the Institute of Company Secretaries of India and the Institute of Cost and Works Accountants of India. She has experience in the field of finance. She joined the Company on October 16, 2015. She is currently the Chief Financial Officer of the Company and she will continue as Chief Financial Officer till a suitable person is appointed. Ms. Komal Gupta has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.).Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.23 (up from ₹3.81 in 3Q 2022). Revenue: ₹1.22b (up 3.6% from 3Q 2022). Net income: ₹91.9m (up 11% from 3Q 2022). Profit margin: 7.5% (up from 7.1% in 3Q 2022). The increase in margin was driven by higher revenue.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Nov 09Windlas Biotech Limited (BSE:543329) announces an Equity Buyback for INR 250 million worth of its shares.Windlas Biotech Limited (BSE:543329) announces a share repurchase program. Under the program, the company will repurchase up to INR 250 million worth of its shares. The shares will be repurchased at a price not exceeding INR 325 per share. As of November 4, 2022, the company had 2,17,94,375 shares issued and outstanding.Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022)Second quarter 2023 results: EPS: ₹5.59 (up from ₹4.11 in 2Q 2022). Revenue: ₹1.35b (up 17% from 2Q 2022). Net income: ₹121.9m (up 47% from 2Q 2022). Profit margin: 9.0% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue.공고 • Sep 20Windlas Biotech Limited Declares A Final Dividend for the Financial Year 2021-22Windlas Biotech Limited at the AGM held on 19 September, 2022, declared a final dividend of INR 3.50 per equity share for the financial year 2021-22.공고 • Aug 27+ 4 more updatesWindlas Biotech Limited Proposes Final Dividend for the Financial Year 2021-22Windlas Biotech Limited at the AGM to be held on 19 September, 2022, proposed to declare a final dividend of INR 3.50 per equity share for the financial year 2021-22.Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022)First quarter 2023 results: EPS: ₹4.50 (up from ₹3.67 in 1Q 2022). Revenue: ₹1.23b (up 11% from 1Q 2022). Net income: ₹98.0m (up 47% from 1Q 2022). Profit margin: 8.0% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue.공고 • Jul 26Windlas Biotech Limited to Report Q1, 2023 Results on Aug 04, 2022Windlas Biotech Limited announced that they will report Q1, 2023 results on Aug 04, 2022공고 • May 13The Board of Directors of Windlas Biotech Limited, At Their Meeting Held on May 12, 2022, Approves the Dividend of INR 3.5 Per ShareThe Board of Directors of Windlas Biotech Limited, at their meeting held on May 12, 2022, have approved the dividend of INR 3.5 per share.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹243, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 36x in the Life Sciences industry in India.Reported Earnings • Feb 03Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.81 (down from ₹6.75 in 3Q 2021). Revenue: ₹1.19b (up 1.0% from 3Q 2021). Net income: ₹83.1m (down 32% from 3Q 2021). Profit margin: 7.0% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.Reported Earnings • Sep 14First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.11b (up 50% from 1Q 2021). Net income: ₹66.9m (up ₹62.2m from 1Q 2021). Profit margin: 6.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹398, the stock trades at a trailing P/E ratio of 45.8x. Average trailing P/E is 45x in the Life Sciences industry in India.Board Change • Aug 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.주주 수익률543329IN Life SciencesIN 시장7D1.9%4.0%-0.3%1Y-10.2%2.7%-1.4%전체 주주 수익률 보기수익률 대 산업: 543329은 지난 1년 동안 2.7%의 수익을 기록한 Indian Life Sciences 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 543329은 지난 1년 동안 -1.4%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 543329's price volatile compared to industry and market?543329 volatility543329 Average Weekly Movement4.0%Life Sciences Industry Average Movement5.4%Market Average Movement6.2%10% most volatile stocks in IN Market9.2%10% least volatile stocks in IN Market3.9%안정적인 주가: 543329는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 543329의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트20011,385Komal Guptawindlas.com계약 개발 및 제조 조직(CDMO)인 윈들라스 바이오테크는 인도 및 국제적으로 의약품을 제조 및 거래합니다. 이 회사는 복잡한 약물 및 제형의 제품 개발, 라이선싱, 상업적 제조를 포함한 CDMO 솔루션을 제공합니다. 또한 건강 보조 식품도 생산합니다.더 보기Windlas Biotech Limited 기초 지표 요약Windlas Biotech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?543329 기초 통계시가총액₹17.56b순이익 (TTM)₹664.56m매출 (TTM)₹9.04b26.1x주가수익비율(P/E)1.9x주가매출비율(P/S)543329는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표543329 손익계산서 (TTM)매출₹9.04b매출원가₹5.61b총이익₹3.43b기타 비용₹2.76b순이익₹664.56m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)32.20총이익률37.92%순이익률7.35%부채/자본 비율5.1%543329의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.7%현재 배당 수익률20%배당 성향543329는 안정적으로 배당을 지급합니까?543329 배당 기록 및 벤치마크 보기다가오는 배당을 받으려면 언제까지 543329를 매수해야 하나요?Windlas Biotech 배당 일정배당락일Jul 16 2026배당 지급일Aug 22 2026배당락일까지 남은 일수0 days배당 지급일까지 남은 일수37 days543329는 안정적으로 배당을 지급합니까?543329 배당 기록 및 벤치마크 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 13:38종가2026/07/15 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Windlas Biotech Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Jul 04Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.04b (up 19% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.4% (down from 8.0% in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • Jul 02Dividend increased to ₹6.30Dividend of ₹6.30 is 8.6% higher than last year. Ex-date: 16th July 2026 Payment date: 22nd August 2026 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 16% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 30% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공고 • Jun 30Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026, at 13:00 Indian Standard Time.
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026
New Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Jul 04Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.04b (up 19% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.4% (down from 8.0% in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • Jul 02Dividend increased to ₹6.30Dividend of ₹6.30 is 8.6% higher than last year. Ex-date: 16th July 2026 Payment date: 22nd August 2026 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 16% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 30% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공고 • Jun 30Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026, at 13:00 Indian Standard Time.
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026
공고 • Apr 17Windlas Biotech Limited (NSEI:WINDLAS) announces an Equity Buyback for 470,000 shares, representing 2.23% for INR 470 million.Windlas Biotech Limited (NSEI:WINDLAS) announces a share repurchase program. Under the program, the company will repurchase up to 470,000 shares, representing 2.23% of its issued share capital, for INR 470 million. The company will repurchase the shares at a price of INR 1,000 per equity share, payable in cash. The buyback is proposed to be made on a proportionate basis. The 15% of the number of equity shares which the company proposes to repurchase or number of equity shares entitled as per the shareholding of small shareholders as on the record date, whichever is higher, shall be reserved for the small shareholders. The record date for the purpose of ascertaining the eligibility of shareholders for the repurchase of shares is April 24, 2026. As of March 31, 2026, the company had 21,106,229 shares outstanding.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹7.12 (vs ₹7.45 in 3Q 2025)Third quarter 2026 results: EPS: ₹7.12 (down from ₹7.45 in 3Q 2025). Revenue: ₹2.38b (up 22% from 3Q 2025). Net income: ₹150.0m (down 3.7% from 3Q 2025). Profit margin: 6.3% (down from 8.0% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jan 28Windlas Biotech Limited to Report Q3, 2026 Results on Feb 05, 2026Windlas Biotech Limited announced that they will report Q3, 2026 results on Feb 05, 2026
Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹8.48 (vs ₹7.49 in 2Q 2025)Second quarter 2026 results: EPS: ₹8.48 (up from ₹7.49 in 2Q 2025). Revenue: ₹2.26b (up 21% from 2Q 2025). Net income: ₹178.0m (up 14% from 2Q 2025). Profit margin: 7.9% (down from 8.4% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Oct 29Windlas Biotech Limited to Report Q2, 2026 Results on Nov 06, 2025Windlas Biotech Limited announced that they will report Q2, 2026 results on Nov 06, 2025
Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹8.43 (vs ₹6.47 in 1Q 2025)First quarter 2026 results: EPS: ₹8.43 (up from ₹6.47 in 1Q 2025). Revenue: ₹2.15b (up 23% from 1Q 2025). Net income: ₹176.6m (up 31% from 1Q 2025). Profit margin: 8.2% (up from 7.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Aug 09Windlas Biotech Limited to Report Q1, 2026 Results on Aug 12, 2025Windlas Biotech Limited announced that they will report Q1, 2026 results on Aug 12, 2025
공고 • Jul 29Windlas Biotech Limited Approves Final Dividend for the Financial Year 2024-25Windlas Biotech Limited announced that at the AGM held on July 28, 2025 approved Final Dividend of INR 5.80/- per Equity Share for the financial year 2024-25.
Upcoming Dividend • Jul 14Upcoming dividend of ₹5.80 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 27 August 2025. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.4%).
공고 • Jul 06Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025, at 13:00 Indian Standard Time.
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹29.19 (vs ₹27.97 in FY 2024)Full year 2025 results: EPS: ₹29.19 (up from ₹27.97 in FY 2024). Revenue: ₹7.78b (up 23% from FY 2024). Net income: ₹609.9m (up 4.8% from FY 2024). Profit margin: 7.8% (down from 9.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 14Windlas Biotech Limited to Report Q4, 2025 Results on May 22, 2025Windlas Biotech Limited announced that they will report Q4, 2025 results on May 22, 2025
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,071, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 320% over the past three years.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹821, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 249% over the past three years.
Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹7.45 (vs ₹7.26 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.45 (up from ₹7.26 in 3Q 2024). Revenue: ₹1.95b (up 20% from 3Q 2024). Net income: ₹155.8m (up 3.2% from 3Q 2024). Profit margin: 8.0% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹844, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 227% over the past three years.
공고 • Feb 03Windlas Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025Windlas Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025
공고 • Jan 10Windlas Biotech Limited Receives Good Manufacturing Practices Certification for New Injectable Facility from the Food Safety & Drugs Administration Authority of UttarakhandWindlas Biotech Limited announced that it has received Good Manufacturing Practices (GMP) certification for its new Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.49 (up from ₹6.75 in 2Q 2024). Revenue: ₹1.92b (up 26% from 2Q 2024). Net income: ₹156.6m (up 12% from 2Q 2024). Profit margin: 8.2% (down from 9.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).
공고 • Nov 05Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Windlas Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,119, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 271% over the past three years.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹997, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 203% over the past three years.
공고 • Sep 26Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at its AGM held on September 24, 2024, approved final dividend of INR 5.50 per equity share for the financial year 2023-24.
Declared Dividend • Aug 31Dividend increased to ₹5.50Dividend of ₹5.50 is 38% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 25% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 79% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.
공고 • Aug 30Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.
공고 • Aug 29Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at the AGM to be held on September 24, 2024, the shareholders proposed a final dividend of INR 5.50 per equity share for the financial year 2023-24.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024)First quarter 2025 results: EPS: ₹6.47 (up from ₹5.79 in 1Q 2024). Revenue: ₹1.79b (up 24% from 1Q 2024). Net income: ₹134.8m (up 12% from 1Q 2024). Profit margin: 7.5% (down from 8.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Aug 02Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Windlas Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹800, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 143% over the past year.
Reported Earnings • May 21Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023)Full year 2024 results: EPS: ₹27.97 (up from ₹19.70 in FY 2023). Revenue: ₹6.44b (up 26% from FY 2023). Net income: ₹581.9m (up 37% from FY 2023). Profit margin: 9.0% (up from 8.3% in FY 2023). The increase in margin was driven by higher revenue.
Buy Or Sell Opportunity • May 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.7% to ₹550. The fair value is estimated to be ₹454, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
공고 • May 12Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024Windlas Biotech Limited announced that they will report Q4, 2024 results on May 20, 2024
Buy Or Sell Opportunity • Apr 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₹558. The fair value is estimated to be ₹459, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
Buy Or Sell Opportunity • Feb 23Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₹547. The fair value is estimated to be ₹456, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023)Third quarter 2024 results: EPS: ₹7.26 (up from ₹4.23 in 3Q 2023). Revenue: ₹1.65b (up 38% from 3Q 2023). Net income: ₹151.0m (up 64% from 3Q 2023). Profit margin: 9.1% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue.
공고 • Jan 31Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024Windlas Biotech Limited announced that they will report Q3, 2024 results on Feb 08, 2024
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹528, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 22x in the Life Sciences industry in India. Total returns to shareholders of 118% over the past year.
Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023)Second quarter 2024 results: EPS: ₹6.75 (up from ₹5.59 in 2Q 2023). Revenue: ₹1.56b (up 18% from 2Q 2023). Net income: ₹140.3m (up 15% from 2Q 2023). Profit margin: 9.0% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses.
공고 • Oct 31Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023Windlas Biotech Limited announced that they will report first half, 2024 results on Nov 08, 2023
공고 • Sep 13Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23Windlas Biotech Limited at the AGM held on September 12, 2023, the shareholders approved a final dividend of INR 4 per equity share for the financial year 2022-23.
Upcoming Dividend • Aug 29Upcoming dividend of ₹4.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 September 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.6%).
공고 • Aug 19+ 1 more updateWindlas Biotech Limited, Annual General Meeting, Sep 12, 2023Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023, at 12:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2023, together with the Reports of the Auditors and the Board of Directors thereon; to consider declare a Final Dividend; to consider and appoint a Director in place of Mr. Hitesh Windlass, Managing Director who is liable to retire by rotation and being eligible, offers himself for re-appointment; and to transact such other business matters.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹384, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past year.
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023)First quarter 2024 results: EPS: ₹5.79 (up from ₹4.50 in 1Q 2023). Revenue: ₹1.47b (up 23% from 1Q 2023). Net income: ₹120.7m (up 23% from 1Q 2023). Profit margin: 8.2% (in line with 1Q 2023).
공고 • Aug 01Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023Windlas Biotech Limited announced that they will report Q1, 2024 results on Aug 08, 2023
Reported Earnings • May 06Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022)Full year 2023 results: EPS: ₹19.70 (up from ₹18.58 in FY 2022). Revenue: ₹5.23b (up 12% from FY 2022). Net income: ₹426.3m (up 12% from FY 2022). Profit margin: 8.1% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses.
공고 • May 06Windlas Biotech Limited Recommends DividendWindlas Biotech Limited at its board meeting held on May 5, 2023 Recommended a Dividend of INR 4.00/- per Equity Share of face value of INR 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM.
공고 • Feb 10Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive OfficerWindlas Biotech Limited announced that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Ms. Komal Gupta as the Chief Executive Officer and Key Managerial Personnel of the Company with effect from February 08, 2023. Ms. Komal Gupta holds a bachelor's degree in commerce from Dr. Babasaheb Ambedkar Marathwada University. She is a fellow member of the Institute of Chartered Accountants of India, an associate member of the Institute of Company Secretaries of India and the Institute of Cost and Works Accountants of India. She has experience in the field of finance. She joined the Company on October 16, 2015. She is currently the Chief Financial Officer of the Company and she will continue as Chief Financial Officer till a suitable person is appointed. Ms. Komal Gupta has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.).
Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.23 (up from ₹3.81 in 3Q 2022). Revenue: ₹1.22b (up 3.6% from 3Q 2022). Net income: ₹91.9m (up 11% from 3Q 2022). Profit margin: 7.5% (up from 7.1% in 3Q 2022). The increase in margin was driven by higher revenue.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Nov 09Windlas Biotech Limited (BSE:543329) announces an Equity Buyback for INR 250 million worth of its shares.Windlas Biotech Limited (BSE:543329) announces a share repurchase program. Under the program, the company will repurchase up to INR 250 million worth of its shares. The shares will be repurchased at a price not exceeding INR 325 per share. As of November 4, 2022, the company had 2,17,94,375 shares issued and outstanding.
Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022)Second quarter 2023 results: EPS: ₹5.59 (up from ₹4.11 in 2Q 2022). Revenue: ₹1.35b (up 17% from 2Q 2022). Net income: ₹121.9m (up 47% from 2Q 2022). Profit margin: 9.0% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue.
공고 • Sep 20Windlas Biotech Limited Declares A Final Dividend for the Financial Year 2021-22Windlas Biotech Limited at the AGM held on 19 September, 2022, declared a final dividend of INR 3.50 per equity share for the financial year 2021-22.
공고 • Aug 27+ 4 more updatesWindlas Biotech Limited Proposes Final Dividend for the Financial Year 2021-22Windlas Biotech Limited at the AGM to be held on 19 September, 2022, proposed to declare a final dividend of INR 3.50 per equity share for the financial year 2021-22.
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022)First quarter 2023 results: EPS: ₹4.50 (up from ₹3.67 in 1Q 2022). Revenue: ₹1.23b (up 11% from 1Q 2022). Net income: ₹98.0m (up 47% from 1Q 2022). Profit margin: 8.0% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue.
공고 • Jul 26Windlas Biotech Limited to Report Q1, 2023 Results on Aug 04, 2022Windlas Biotech Limited announced that they will report Q1, 2023 results on Aug 04, 2022
공고 • May 13The Board of Directors of Windlas Biotech Limited, At Their Meeting Held on May 12, 2022, Approves the Dividend of INR 3.5 Per ShareThe Board of Directors of Windlas Biotech Limited, at their meeting held on May 12, 2022, have approved the dividend of INR 3.5 per share.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹243, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 36x in the Life Sciences industry in India.
Reported Earnings • Feb 03Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.81 (down from ₹6.75 in 3Q 2021). Revenue: ₹1.19b (up 1.0% from 3Q 2021). Net income: ₹83.1m (down 32% from 3Q 2021). Profit margin: 7.0% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Reported Earnings • Sep 14First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.11b (up 50% from 1Q 2021). Net income: ₹66.9m (up ₹62.2m from 1Q 2021). Profit margin: 6.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹398, the stock trades at a trailing P/E ratio of 45.8x. Average trailing P/E is 45x in the Life Sciences industry in India.
Board Change • Aug 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
